Transmission of coronavirus by nebulizer: a serious, underappreciated risk.
作者信息
Amirav Israel, Newhouse Michael T
机构信息
Pediatric respirologist, University of Alberta, Edmonton, Alta.; Dana-Dwek Childrens' Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.
Respirologist, McMaster University, Hamilton, Ont.
出版信息
CMAJ. 2020 Mar 30;192(13):E346. doi: 10.1503/cmaj.75066.
Abstract
摘要
相似文献
1
Transmission of coronavirus by nebulizer: a serious, underappreciated risk.通过雾化器传播冠状病毒：一种严重但未得到充分重视的风险。
CMAJ. 2020 Mar 30;192(13):E346. doi: 10.1503/cmaj.75066.
2
A large-volume nebulizer would not be an infectious source for severe acute respiratory syndrome.大容量雾化器不会成为严重急性呼吸综合征的传染源。
Infect Control Hosp Epidemiol. 2004 Dec;25(12):1113-5. doi: 10.1086/502353.
3
Albuterol delivery in an in vitro pediatric ventilator lung model: comparison of jet, ultrasonic, and mesh nebulizers.在体外小儿呼吸机肺模型中输送沙丁胺醇：比较射流、超声和网孔雾化器。
Pediatr Crit Care Med. 2013 Feb;14(2):e98-102. doi: 10.1097/PCC.0b013e3182712783.
4
Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.沙丁胺醇雾化的物理化学特性及效率：体外儿科模型中三种气雾剂类型的比较
Respir Care. 2015 Jan;60(1):38-46. doi: 10.4187/respcare.02490. Epub 2014 Dec 16.
5
In vitro comparison of five nebulizers during noninvasive ventilation: analysis of inhaled and lost doses.无创通气期间五种雾化器的体外比较：吸入剂量与损失剂量分析
J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):430-40. doi: 10.1089/jamp.2013.1070.
6
[Time course of drug concentrations in nebulizers and nebulized solutions].[雾化器和雾化溶液中药物浓度的时间进程]
Arerugi. 1992 Jul;41(7):772-7.
7
Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand.药物雾化器性能。稀释剂体积、雾化器流量和雾化器品牌的影响。
Chest. 1996 Aug;110(2):498-505. doi: 10.1378/chest.110.2.498.
8
A review of the technical aspects of drug nebulization.药物雾化技术方面的综述。
Pharm World Sci. 2000 Jun;22(3):75-81. doi: 10.1023/a:1008786600530.
9
Dispensing home nebulizers for acute wheezing from the hospital is cost-effective.从医院发放家用雾化器用于急性喘息是具有成本效益的。
Am J Emerg Med. 2000 Mar;18(2):164-7. doi: 10.1016/s0735-6757(00)90010-x.
10
Aerosol delivery during spontaneous breathing with different types of nebulizers- in vitro/ex vivo models evaluation.不同类型雾化器在自主呼吸时的气溶胶输送 - 体外/离体模型评估。
Pulm Pharmacol Ther. 2018 Feb;48:225-231. doi: 10.1016/j.pupt.2017.12.006. Epub 2017 Dec 19.
引用本文的文献
1
A Novel Common Canister Protocol for Albuterol Sulfate Metered Dose Inhalers: Conservation Strategy and Clinical Outcomes Amid COVID-19 Pandemic.一种新型硫酸沙丁胺醇定量气雾剂共用药罐方案：COVID-19大流行期间的节约策略及临床结果
Hosp Pharm. 2024 Dec;59(6):631-637. doi: 10.1177/00185787241254994. Epub 2024 May 23.
2
The influence of novel coronavirus pneumonia on chronic disease management of asthma-a narrative review.新型冠状病毒肺炎对哮喘慢性病管理的影响——一项叙述性综述
J Thorac Dis. 2024 Feb 29;16(2):1590-1600. doi: 10.21037/jtd-23-1139. Epub 2024 Feb 23.
3
Emerging Roles of Malaysian Pharmacists in Asthma Management Amidst the COVID-19 Pandemic: A Narrative Review.新冠疫情期间马来西亚药剂师在哮喘管理中的新角色：叙事性综述
Malays J Med Sci. 2023 Aug;30(4):33-47. doi: 10.21315/mjms2023.30.4.4. Epub 2023 Aug 24.
4
COVID-19 Therapeutic Potential of Natural Products.天然产物在 COVID-19 治疗方面的潜力。
Int J Mol Sci. 2023 May 31;24(11):9589. doi: 10.3390/ijms24119589.
5
Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects.法匹拉韦经肺部给药在大鼠体内可达到高局部浓度，且不会引起肺部氧化损伤或全身副作用。
Pharmaceutics. 2022 Nov 4;14(11):2375. doi: 10.3390/pharmaceutics14112375.
6
SARS-CoV-2 in the Air Surrounding Patients during Nebulizer Therapy.雾化治疗期间患者周围空气中的新型冠状病毒 2 型
Can J Infect Dis Med Microbiol. 2022 Sep 17;2022:9297974. doi: 10.1155/2022/9297974. eCollection 2022.
7
A full-face mask for protection against respiratory infections.全面罩，用于防止呼吸道感染。
Biomed Eng Online. 2022 Sep 5;21(1):62. doi: 10.1186/s12938-022-01027-1.
8
Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: characterization, stability, cytotoxicity, and antiviral activity using real time cell analysis.用于 COVID-19 治疗的吸入用利巴韦林溶液的肺部递药：使用实时细胞分析进行的表征、稳定性、细胞毒性和抗病毒活性。
Drug Deliv. 2022 Dec;29(1):2846-2854. doi: 10.1080/10717544.2022.2118398.
9
Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges.2019冠状病毒病大流行期间哮喘患者的管理：应对挑战的病理生理学考量
Beni Suef Univ J Basic Appl Sci. 2022;11(1):20. doi: 10.1186/s43088-022-00204-4. Epub 2022 Feb 5.
10
School Asthma Care During COVID-19: What We Have Learned and What We Are Learning.COVID-19 期间的学校哮喘管理：我们的经验教训和正在学习的内容。
J Allergy Clin Immunol Pract. 2022 Feb;10(2):453-459. doi: 10.1016/j.jaip.2021.11.020. Epub 2021 Nov 27.
本文引用的文献
1
Communication, transparency key as Canada faces new coronavirus threat.随着加拿大面临新冠病毒威胁，沟通与透明度至关重要。
CMAJ. 2020 Feb 18;192(7):E171-E172. doi: 10.1503/cmaj.1095846.
2
Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises.医疗场所中感染气溶胶传播及通风控制所涉及的因素。
J Hosp Infect. 2006 Oct;64(2):100-14. doi: 10.1016/j.jhin.2006.05.022. Epub 2006 Aug 17.
3
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.用于急性哮喘β受体激动剂治疗的储物罐（ spacer）与雾化器的比较
Cochrane Database Syst Rev. 2006 Apr 19(2):CD000052. doi: 10.1002/14651858.CD000052.pub2.
Zotero 插件